Pfizer launches vaccine test in children To view this email as a web page,
click here Vir, GSK race COVID-19 antibody to FDA for emergency nod 2020 offered a 'perfect storm' for cybercriminals with ransomware attacks costing the industry $21B Pfizer launches COVID-19 vaccine test in children as new data support mRNA shots in pregnant women WTW survey: Few employers think COVID-19 vaccines should be mandatory for workers BioNTech nabs EU approval for former Novartis plant tapped in COVID-19 vaccine production push AstraZeneca partner takes nasal COVID-19 vaccine into phase 1 Senate passes bill to extend Medicare sequester fix through 2021 COVID-19 tracker: More J&J shots on the way; Vir, GSK submit antibody to FDA Featured Story | By Amirah Al Idrus Vir Biotechnology and GlaxoSmithKline have asked the FDA for emergency use authorization for their coronavirus-fighting dual-action antibody. The duo is seeking an emergency OK for the treatment of adults and adolescents aged 12 and older with mild to moderate COVID-19 who are at risk of dying from or needing hospitalization. read more |
| |
|---|
|
Top Stories By Brian T. Horowitz Ransomware attacks cost the healthcare industry $20.8 billion in downtime in 2020, which is double the number from 2019. Here's why cybersecurity experts say 2020 offered a perfect storm for cybercriminals and a critical tipping point for the cyber arms race. read more By Eric Sagonowsky While COVID-19 shots have proven effective in clinical trials—and in the real world, too—relatively little is known about how well they work in children and pregnant women. Pfizer, Moderna and J&J aim to change that. The leading players are setting out with studies in children just as new data support mRNA shots in pregnant women. read more By Paige Minemyer Few employers believe vaccines should be mandatory before employees return to the workplace, according to a new survey from Willis Towers Watson. read more By Fraiser Kansteiner BioNTech won approval from the European Medicines Agency to start making and supplying partners with vaccine drug product from the Marburg, Germany, facility it picked up from Novartis last fall. BioNTech is gunning to deliver 250 million doses from the site in the first half of the year, and the plant could ultimately hit annual capacity of 1 billion doses. read more By Nick Paul Taylor The University of Oxford has begun a phase 1 clinical trial of a nasal spray formulation of its AstraZeneca-partnered COVID-19 vaccine. read more By Robert King The Senate passed legislation Thursday intended to extend through 2021 a moratorium on a 2% cut to Medicare payments that was installed under the sequester. read more By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky After a slow start for Johnson & Johnson's vaccine rollout, 11 million more doses are on the way. Plus, GSK and Vir submitted their antibody to the FDA for a potential emergency authorization. And more. read more |
|
